These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 10339597)

  • 1. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
    Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
    Jeyakumar M; Norflus F; Tifft CJ; Cortina-Borja M; Butters TD; Proia RL; Perry VH; Dwek RA; Platt FM
    Blood; 2001 Jan; 97(1):327-9. PubMed ID: 11133779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
    Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
    Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
    Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
    Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
    Denny CA; Heinecke KA; Kim YP; Baek RC; Loh KS; Butters TD; Bronson RT; Platt FM; Seyfried TN
    J Neurochem; 2010 Jun; 113(6):1525-35. PubMed ID: 20374428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
    Platt FM; Neises GR; Reinkensmeier G; Townsend MJ; Perry VH; Proia RL; Winchester B; Dwek RA; Butters TD
    Science; 1997 Apr; 276(5311):428-31. PubMed ID: 9103204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.
    Arthur JR; Lee JP; Snyder EY; Seyfried TN
    Neurochem Res; 2012 Jun; 37(6):1335-43. PubMed ID: 22367451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate deprivation therapy in juvenile Sandhoff disease.
    Wortmann SB; Lefeber DJ; Dekomien G; Willemsen MA; Wevers RA; Morava E
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S307-11. PubMed ID: 19898952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
    Jeyakumar M; Smith DA; Williams IM; Borja MC; Neville DC; Butters TD; Dwek RA; Platt FM
    Ann Neurol; 2004 Nov; 56(5):642-9. PubMed ID: 15505823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
    Sango K; McDonald MP; Crawley JN; Mack ML; Tifft CJ; Skop E; Starr CM; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1996 Nov; 14(3):348-52. PubMed ID: 8896570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease.
    Yamaguchi A; Katsuyama K; Suzuki K; Kosaka K; Aoki I; Yamanaka S
    J Mol Med (Berl); 2003 Mar; 81(3):185-93. PubMed ID: 12682727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
    Ashe KM; Bangari D; Li L; Cabrera-Salazar MA; Bercury SD; Nietupski JB; Cooper CG; Aerts JM; Lee ER; Copeland DP; Cheng SH; Scheule RK; Marshall J
    PLoS One; 2011; 6(6):e21758. PubMed ID: 21738789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
    Pelled D; Lloyd-Evans E; Riebeling C; Jeyakumar M; Platt FM; Futerman AH
    J Biol Chem; 2003 Aug; 278(32):29496-501. PubMed ID: 12756243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic correction in microglia derived from Sandhoff disease model mice.
    Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
    J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice.
    Denny CA; Kasperzyk JL; Gorham KN; Bronson RT; Seyfried TN
    J Neurosci Res; 2006 May; 83(6):1028-38. PubMed ID: 16521125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoters for the human beta-hexosaminidase genes, HEXA and HEXB.
    Norflus F; Yamanaka S; Proia RL
    DNA Cell Biol; 1996 Feb; 15(2):89-97. PubMed ID: 8634145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice.
    Wu YP; Proia RL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8425-30. PubMed ID: 15155903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate reduction therapy for glycosphingolipid storage disorders.
    Lachmann RH; Platt FM
    Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
    Marshall J; Nietupski JB; Park H; Cao J; Bangari DS; Silvescu C; Wilper T; Randall K; Tietz D; Wang B; Ying X; Leonard JP; Cheng SH
    Mol Ther; 2019 Aug; 27(8):1495-1506. PubMed ID: 31208914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
    Platt FM; Jeyakumar M; Andersson U; Priestman DA; Dwek RA; Butters TD; Cox TM; Lachmann RH; Hollak C; Aerts JM; Van Weely S; Hrebícek M; Moyses C; Gow I; Elstein D; Zimran A
    J Inherit Metab Dis; 2001 Apr; 24(2):275-90. PubMed ID: 11405346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.